Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: transparency in reporting of conflict of interest is an increasingly important aspect of publication in medical journals. Publication of large industry-supported trials may generate many citations and journal income through reprint sales and thereby be a source of conflicts of interest for journals. We investigated industry-supported trials' influence on journal impact factors and revenue. METHODS AND FINDINGS: we sampled six major medical journals (Annals of Internal Medicine, Archives of Internal Medicine, BMJ, JAMA, The Lancet, and New England Journal of Medicine [NEJM]). For each journal, we identified randomised trials published in 1996-1997 and 2005-2006 using PubMed, and categorized the type of financial support. Using Web of Science, we investigated citations of industry-supported trials and the influence on journal impact factors over a ten-year period. We contacted journal editors and retrieved tax information on income from industry sources. The proportion of trials with sole industry support varied between journals, from 7% in BMJ to 32% in NEJM in 2005-2006. Industry-supported trials were more frequently cited than trials with other types of support, and omitting them from the impact factor calculation decreased journal impact factors. The decrease varied considerably between journals, with 1% for BMJ to 15% for NEJM in 2007. For the two journals disclosing data, income from the sales of reprints contributed to 3% and 41% of the total income for BMJ and The Lancet in 2005-2006. CONCLUSIONS: publication of industry-supported trials was associated with an increase in journal impact factors. Sales of reprints may provide a substantial income. We suggest that journals disclose financial information in the same way that they require them from their authors, so that readers can assess the potential effect of different types of papers on journals' revenue and impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The History and Meaning of the Journal Impact Factor
Garfield, E. (2006) · JAMA · doi:10.1001/jama.295.1.90 · Cited by 2,770 · cited 1×
“The impact factor for a given year is calculated as the number of citations in that year to papers published in the two previous years, divided by the number of citable papers published in the two previous years [6].”
BackgroundPharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 2×
“Interestingly, industry trials more often have positive results than nonindustry trials [14], the conclusions in negative trials are often presented in such a way that they appear to be more positive than they actually are [15], and positive industry trials are more cited than negative ones [12,13].”
BackgroundBoutron, I. (2010) · JAMA · doi:10.1001/jama.2010.651 · Cited by 842 · cited 1×
“Interestingly, industry trials more often have positive results than nonindustry trials [14], the conclusions in negative trials are often presented in such a way that they appear to be more positive than they actually are [15], and positive industry trials are more cited than negative ones [12,13].”
BackgroundPrevalence of Articles With Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals
Flanagin, A. (1998) · JAMA · doi:10.1001/jama.280.3.222 · Cited by 553
Importance of the Lay Press in the Transmission of Medical Knowledge to the Scientific Community
Phillips, D. P., Kanter, E. J., Bednarczyk, B., & Tastad, P. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110173251620 · Cited by 399
Cited by
Public Availability of Published Research Data in High-Impact Journals
Alsheikh-Ali, A. A., Qureshi, W., Al-Mallah, M. H., & Ioannidis, J. P. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024357 · Cited by 363
“Indeed, widespread availability of clinical trial data may be hampered by financial incentives of journals to publish industry-sponsored trials, many of which may be bound by confidentiality agreements [22,23,24].”
BackgroundHuman Gut Microbiota: Repertoire and Variations
Lagier, J.-C., Million, M., Hugon, P., Armougom, F., & Raoult, D. (2012) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2012.00136 · Cited by 329
“Excellence R Us”: university research and the fetishisation of excellence
Moore, S., Neylon, C., Paul Eve, M., Paul O’Donnell, D., & Pattinson, D. (2017) · Palgrave Communications · doi:10.1057/palcomms.2016.105 · Cited by 264
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Mandrioli, D., Kearns, C. E., & Bero, L. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162198 · Cited by 160
Metadata
- Authors
- Lundh, A., Barbateskovic, M., Hróbjartsson, A., & Gøtzsche, P. C.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-10-26
- Volume
- 7
- Issue
- 10
- Pages
- e1000354
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2092014861
- Cited by
- 123
- References
- 5
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study. https://app.cochat.ai/papers/10.1371/journal.pmed.1000354
- The paper
- Lundh, A., Barbateskovic, M., Hróbjartsson, A., & Gøtzsche, P. C. (2010). Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1000354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.